Get Smarter on Biotech in 5 Minutes a Day.
Focused insights — expertly curated, clearly delivered, ready for action.
Get the Daily Brief
What’s in Today’s Brief? (August 25th Preview)
-
Alzheimer’s blood biomarker clearance
Roche and Eli Lilly won U.S. FDA clearance for the Elecsys Phospho-Tau (217P) Plasma blood test, designed to detect amyloid pathology tied to Alzheimer’s disease. The assay is intended for people ages 55 and older who present with signs, symptoms, or complaints of cognitive decline. It adds to the growing menu of blood-based biomarkers that can help clinicians identify Alzheimer’s pathology without waiting for more invasive or imaging-based confirmation. For Roche and Lilly, the decision extends their footprint in plasma biomarker testing and reinforces a shift toward earlier, easier-to-scale diagnostics in neurodegeneration.
-
Gene therapy safety holds for Hunter syndrome
Regenerxbio’s Hunter syndrome gene therapy programs hit another regulatory snag, with the FDA placing clinical holds tied to asymptomatic spine MRI findings. The company said it no longer expects to file for FDA approval of its RGX-121 (clemidsogene lanparvovec) in the near term after discovering spine MRI masses in five patients enrolled in its Campsiite study, prompting a stop to testing. The new hold follows a prior Hunter-related pause earlier this year. STAT+ previously reported Regenxbio’s trial pauses for safety reasons, and the latest decision adds urgency for stakeholders tracking AAV gene therapy risk signals—especially around latent imaging abnormalities.
-
CDK4/6 benefit depends on menopause status
A new systematic review and meta-analysis of phase III trials suggests menopause status can change outcomes with adjuvant CDK4/6 inhibitors in early hormone-receptor-positive breast cancer. The analysis focused on whether the effectiveness of CDK4/6 inhibitor–based regimens varies between premenopausal and postmenopausal patients, aiming to inform how clinicians individualize extended adjuvant strategies. For the CDK4/6 class, the work may sharpen real-world decision-making where treatment selection increasingly depends on biology and patient context rather than menopausal status alone.
-
Moderna and Merck melanoma vaccine delivers positive Phase 3 readout
Moderna and Merck reported positive Phase 3 topline results for their mRNA cancer vaccine intismeran autogene in an individualized neoantigen therapy regimen. In the INTerpath-001 study (1,137 volunteers), patients receiving intismeran plus Merck’s Keytruda (pembrolizumab) showed improved recurrence-free survival and distant metastasis-free survival versus Keytruda alone. The announcement has renewed attention on personalized mRNA approaches in melanoma after skepticism from investors. Beyond the companies, the result also lifted sentiment toward sequencing-related suppliers due to the genomics-intensive nature of building individualized neoantigen vaccines.
-
Roche licensing a Hanmi obesity drug that aims to preserve lean mass
Roche agreed to license Hanmi Pharmaceutical’s early-stage obesity candidate HM-17321, part of a strategy to drive weight loss while preserving muscle. The deal reportedly includes $190 million upfront consideration, with total payments potentially reaching $2.3 billion, and covers development, manufacturing, and commercialization worldwide while excluding South Korea. The mechanism centers on activating a receptor in skeletal muscle to increase muscle mass and reduce fat. With Roche already active in obesity combinations and mono-therapies, this acquisition of a differentiating, non-incretin approach signals continued diversification of obesity pipelines beyond GLP-1-centered regimens.
...and 5 more selected Biotech stories in today’s full edition — or archive.
Why BioBriefs?
- Expertly curated. We scan 200+ sources daily to deliver only what matters.
- Smart context. Each brief explains why it matters and who it impacts.
- Made for pros. Trusted by founders, scientists, investors, and strategists.
Who Reads BioBriefs?
- Biotech founders & execs
- R&D and Clinical leads
- Life sciences investors
- Regulators and BD pros
- Translational scientists and tech scouts
Stay sharp. Be first to what’s next.
About BioBriefs
We’re a team of biotech analysts, technical writers, and founders who know what it’s like to scan 40 tabs and still miss what matters. BioBriefs was built to solve that. We track the signals, condense the insights, and get them to you before your day starts.